TY - JOUR
T1 - Chronic kidney disease
AU - Romagnani, Paola
AU - Agarwal, Rajiv
AU - Chan, Juliana C.N.
AU - Levin, Adeera
AU - Kalyesubula, Robert
AU - Karam, Sabine
AU - Nangaku, Masaomi
AU - Rodríguez-Iturbe, Bernardo
AU - Anders, Hans Joachim
N1 - Publisher Copyright:
© Springer Nature Limited 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death. Kidney failure without access to kidney replacement therapy is fatal — a reality in many regions of the world. CKD can be the consequence of a single cause, but CKD in adults frequently relates rather to sequential injuries accumulating over the life course or to the presence of concomitant risk factors. The shared pathomechanism of CKD progression is the irreversible loss of kidney cells or nephrons together with haemodynamic and metabolic overload of the remaining nephrons, leading to further loss of kidney cells or nephrons. The management of patients with CKD focuses on early detection and on controlling all modifiable risk factors. This approach includes reducing the overload of the remaining nephrons with inhibitors of the renin–angiotensin system and the sodium-glucose transporter 2, as well as disease-specific drug interventions, if available. Hypertension, anaemia, metabolic acidosis and secondary hyperparathyroidism contribute to cardiovascular morbidity and reduced quality of life, and require diagnosis and treatment.
AB - Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death. Kidney failure without access to kidney replacement therapy is fatal — a reality in many regions of the world. CKD can be the consequence of a single cause, but CKD in adults frequently relates rather to sequential injuries accumulating over the life course or to the presence of concomitant risk factors. The shared pathomechanism of CKD progression is the irreversible loss of kidney cells or nephrons together with haemodynamic and metabolic overload of the remaining nephrons, leading to further loss of kidney cells or nephrons. The management of patients with CKD focuses on early detection and on controlling all modifiable risk factors. This approach includes reducing the overload of the remaining nephrons with inhibitors of the renin–angiotensin system and the sodium-glucose transporter 2, as well as disease-specific drug interventions, if available. Hypertension, anaemia, metabolic acidosis and secondary hyperparathyroidism contribute to cardiovascular morbidity and reduced quality of life, and require diagnosis and treatment.
UR - http://www.scopus.com/inward/record.url?scp=85217357303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85217357303&partnerID=8YFLogxK
U2 - 10.1038/s41572-024-00589-9
DO - 10.1038/s41572-024-00589-9
M3 - Article
C2 - 39885176
AN - SCOPUS:85217357303
SN - 2056-676X
VL - 11
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 8
ER -